Khalid O Dar, MD
img_Khalid O Dar
ASSISTANT PROFESSOR | Medicine, Hematology and Medical Oncology
Are you a patient?
Specialties
Internal Medicine, Hematology-Oncology, Cancer (Oncology)
Oncology
As a fellow my research project focused on the drug development of the topoisomerase I inhibitor topotecan. Using Western Blot assays I quantified the topoisomerase I copy numbers in a variety of human tumors to identify potential cancers that may be susceptible to this therapy. I was also involved in developing a mouse in vivo system for combination immuno-chemotherapy using xenografts of human mammary tumors in mice.

MBBS, Charing Cross & Westminster Medical School

Residency, Surgery (General Surgery), Queen Mary's Hospital

Residency, General Practice, St. Helier Hospital

Residency, Internal Medicine, Princess Margaret Hospital

Residency, Internal Medicine, Joyce Green Hospital

Residency, Internal Medicine, Staten Island University Hospital-North

Fellowship, Hematology & Oncology, Mount Sinai Hospital

Physicians and scientists on the faculty of the Icahn School of Medicine at Mount Sinai often interact with pharmaceutical, device, biotechnology companies, and other outside entities to improve patient care, develop new therapies and achieve scientific breakthroughs. In order to promote an ethical and transparent environment for conducting research, providing clinical care and teaching, Mount Sinai requires that salaried faculty inform the School of their outside financial relationships.

Dr. Dar has not yet completed reporting of Industry relationships.

Mount Sinai's faculty policies relating to faculty collaboration with industry are posted on our website. Patients may wish to ask their physician about the activities they perform for companies.